MARKET

SVRA

SVRA

Savara Inc
NASDAQ
6.03
+0.13
+2.20%
After Hours: 6.03 0 0.00% 17:29 06/29 EDT
OPEN
5.90
PREV CLOSE
5.90
HIGH
6.04
LOW
5.85
VOLUME
1.54M
TURNOVER
--
52 WEEK HIGH
7.01
52 WEEK LOW
1.980
MARKET CAP
1.24B
P/E (TTM)
-10.8006
1D
5D
1M
3M
1Y
5Y
1D
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?
Simply Wall St · 5h ago
Weekly Report: what happened at SVRA last week (0622-0626)?
Weekly Report · 15h ago
Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?
Simply Wall St · 1d ago
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
The Motley Fool · 2d ago
Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million
PUBT · 06/23 00:18
Weekly Report: what happened at SVRA last week (0615-0619)?
Weekly Report · 06/22 09:22
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)?
Simply Wall St · 06/20 19:24
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)
TipRanks · 06/15 14:30
More
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.